Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

Benzinga Newsdesk www.benzinga.com Positive 92.3%